aTyr Pharma (NASDAQ:ATYR) Given "Market Perform" Rating at Leerink Partners

Key Points

• aTyr Pharma's stock has received a **"market perform"** rating from Leerink Partners, maintaining consistency amidst fluctuating analyst opinions.
• The company's shares have seen mixed ratings, with **Wells Fargo raising its price target from $17 to $25** and additional revisions from other firms affecting overall consensus ratings.
• aTyr Pharma's stock suffered a decline on Monday, trading at **$1.12**, down by **$4.92**, highlighting current volatility in its market performance.

aTyr Pharma (NASDAQ:ATYR - Get Free Report)'s stock had its "market perform" rating reaffirmed by equities research analysts at Leerink Partners in a research report issued to clients and investors on Monday, MarketBeat.com reports.

Several other brokerages have also issued reports on ATYR. Cantor Fitzgerald lowered shares of aTyr Pharma from an "overweight" rating to a "neutral" rating in a report on Monday. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of aTyr Pharma in a report on Wednesday, June 4th. Wells Fargo & Company lifted their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, June 20th. Jefferies Financial Group boosted their target price on shares of aTyr Pharma from $9.00 to $17.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Finally, Wall Street Zen cut shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, aTyr Pharma currently has a consensus rating of "Hold" and an average target price of $23.25.

aTyr Pharma Trading Up 12.3%

Shares of NASDAQ:ATYR traded up $0.13 during trading on Monday, reaching $1.15. The company's stock had a trading volume of 31,016,090 shares, compared to its average volume of 3,737,402. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. aTyr Pharma has a 12 month low of $1.00 and a 12 month high of $7.29. The firm's 50 day simple moving average is $5.28 and its two-hundred day simple moving average is $4.37. The stock has a market capitalization of $112.20 million, a PE ratio of -1.43 and a beta of 1.01.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). On average, research analysts predict that aTyr Pharma will post -0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On aTyr Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Octagon Capital Advisors LP raised its position in aTyr Pharma by 7.5% during the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company's stock worth $19,367,000 after acquiring an additional 268,000 shares during the last quarter. Geode Capital Management LLC raised its position in aTyr Pharma by 126.1% during the second quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company's stock worth $10,639,000 after acquiring an additional 1,170,276 shares during the last quarter. Woodline Partners LP purchased a new stake in shares of aTyr Pharma during the fourth quarter worth about $6,092,000. Millennium Management LLC grew its holdings in shares of aTyr Pharma by 334.5% during the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company's stock worth $4,829,000 after buying an additional 1,231,052 shares in the last quarter. Finally, Ally Bridge Group NY LLC grew its holdings in shares of aTyr Pharma by 11.0% during the first quarter. Ally Bridge Group NY LLC now owns 777,020 shares of the company's stock worth $2,347,000 after buying an additional 77,290 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company's stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.